• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Application of gene therapy on squamous cell carcinoma of the head and neck (SCCHN)

Research Project

Project/Area Number 12671685
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Otorhinolaryngology
Research InstitutionNihon University

Principal Investigator

ENDO Sohei  Sch. Of Med., Dept. of ORL-HNS Assistant Prof., 医学部, 講師 (80246876)

Co-Investigator(Kenkyū-buntansha) MATSUYAMA Kazuo  Sch. Of Med., Dept. of ORL-HNS, 医学部, 助手 (40333108)
KIJIMA Taro  Sch. Of Med., Dept. of ORL-HNS, 医学部, 助手 (40256863)
野口 雄五  日本大学, 医学部, 助手 (30318422)
清水 一史  日本大学, 医学部, 教授 (50004677)
木田 亮紀  日本大学, 医学部, 教授 (00096801)
Project Period (FY) 2000 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 2002: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2001: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2000: ¥1,600,000 (Direct Cost: ¥1,600,000)
Keywordssquamous cell carcinoma / head and neck / gene therapy / antisense plasmid vector / transforming growth factor (TGF)-alpha / liposome / cisplatin
Research Abstract

According to recent meta-analyses, chemotherapy has been proved to be beneficial in improving survival for the patients with squamous cell carcinoma of the head and neck (SCCHN). Cisplatin is the standard chemotherapeutic agent in treating SCCHN patients. Therefore cisplatin resistant is one of the major obstacles in improving survival. At first we established cisplatin-resistant SCCHN cell lines. Then we developed animal model where subcutaneously inoculated SCCHN tumor progresses even with cisplatin administration which were weekly injected intra-peritoneally (IP).
On the other hand, we have also shown that antisense (AS) gene delivery targeting transforming growth factor (TGF)-α was effective in suppressing SCCHN tumor growth in vivo.
This time we succeeded to show the results where simultaneous administration of TGF-α AS plasmid vector injected topically enhanced anti-tumor effects of cisplatin on SCCHN in vivo. This animal design provides a good preclinical model for the treatment of cisplatin-resistant SCCHN.

Report

(4 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report
  • 2000 Annual Research Report
  • Research Products

    (5 results)

All Other

All Publications (5 results)

  • [Publications] Endo S, et al.: "TGF-α antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo"Gene Therapy. 7. 1906-1914 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] S Endo, et al.: "TGF-α antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo"Gene Ther.. 1906-1914 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2002 Final Research Report Summary
  • [Publications] Endo S, et al.: "TGF-α antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo"Gene Therapy. 7. 1906-1914 (2000)

    • Related Report
      2002 Annual Research Report
  • [Publications] S Endo, et al.: "TGF-α antisense gene therapy inhibits head and neck aquamous cell carcinoma growth in vivo"Gene Therapy. 7. 1906-1914 (2000)

    • Related Report
      2001 Annual Research Report
  • [Publications] S Endo, et al.: "TGF-α antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo"Gene Therapy. 7. 1906-1914 (2000)

    • Related Report
      2000 Annual Research Report

URL: 

Published: 2000-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi